Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Pancreatic Neoplasms 1Melanoma 1Glioma 1Brain Neoplasms 1

Interventions

Radiotherapy 18Temozolomide 11Vincristine 10Filgrastim 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Carboplatin 8Cyclophosphamide 7Radiotherapy, Intensity-Modulated 6Cisplatin 6Radiotherapy, Conformal 5Radiosurgery 5Peripheral Blood Stem Cell Transplantation 5Lomustine 5etoposide phosphate 4Thiotepa 3Immunohistochemistry 3Chemotherapy, Adjuvant 3Bevacizumab 3sargramostim 2Topotecan 2Psychiatric Rehabilitation 2Proton Therapy 2Procarbazine 2Microarray Analysis 2Mesna 2Mental Status and Dementia Tests 2Memantine 2In Situ Hybridization, Fluorescence 2Ifosfamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Brain Neoplasms × trametinib × Clear all
NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡